Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Supply issues are a common frustration for many patients
Figures were generated, and statistical analyses were carried out using GraphPad Prism (version 10, California, United States)
General PA criteria include: BMI threshold: BMI 30 (obesity), or BMI 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, or cardiovascular disease) Documentation of medical necessity: Clinical notes confirming obesity diagnosis, comorbidities, and treatment rationale from a licensed provider Prior lifestyle program participation: Many plans require documentation of participation in a structured diet and exercise program for a defined period (typically 36 months) before GLP-1 medications are authorized Non-diabetic indication: For Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide weight loss dose), the weight management indication must be documented separately from diabetes management Step therapy: Some Cigna plans may require an oral agent (such as phentermine or Contrave) trial before authorizing higher-cost GLP-1 medications Ongoing authorization: GLP-1 PA approvals are typically renewable annually and may require documentation of 5% body weight reduction to continue coverage Klarity Healths clinical team may assist with the prior authorization process
Degradation is a chemical reality
US$ 27.51
US$ 21.85
US$ 25.31
US$ 20.87
